Nephrology- University of Rochester Faculty

Contact this Expert Witness

  • Phone: 585-512-8978‬
  • Cell: 585-512-8978‬

Specialties & Experience of this Expert Witness

General Specialties:

Nephrology

Keywords/Search Terms:

Hemodialysis, Peritoneal Dialysis, Acute kidney injury, Chronic kidney disease, Electrolyte disorders, Acid base disorders, Hypertension

Education:

MD, SUNY Health Science Center at Syracuse; MS, University of Rochester Medical Center ; MPH,

Years in Practice:

21

Number of Times Deposed/Testified in Last 4 Yrs:

2

Additional Information

Dr. Scott Liebman is a board-certified nephrologist and Professor of Medicine at the University of Rochester, where he has served on the faculty since 2004. He brings over 20 years of clinical, academic, and leadership experience in nephrology, with a focus on addressing issues surrounding chronic kidney disease, acute kidney injury, dialysis care, and fluid and electrolyte disorders. He earned his MD from Upstate Medical University in Syracuse, NY, completed his internal medicine residency at Mount Sinai Hospital in New York, and his nephrology fellowship at the University of Colorado. He also holds a Master of Public Health degree from the University of Rochester and is board-certified in nephrology and lifestyle medicine. Dr. Liebman has extensive experience in managing kidney diseases, dialysis modalities, and electrolyte disturbances. He serves as medical director for a dialysis clinic and provides expert nephrology care in both inpatient and outpatient settings. An accomplished educator, Dr. Liebman has been actively involved in teaching medical students, residents, and fellows, and has held leadership roles in medical education. He has published peer-reviewed articles and textbook chapters and has contributed to advancing nephrology through various leadership positions. Dr. Liebman is available for expert witness and consulting services related to nephrology, including dialysis complications, diagnosis and management of kidney diseases, electrolyte abnormalities, dialysis access and modality decisions, hypertension, and standard of care issues.